RGX-202: REGENXBIO’s investigational gene therapy for the treatment of Duchenne Muscular Dystrophy (DMD)

REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital share updates about RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne) and trials: the AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 and AFFINITY BEYOND™, an antibody assessment study in boys with Duchenne. 

Recorded Wednesday, February 1st, 2023.


Aravindhan Veerapandiyan, MD

Aravindhan Veerapandiyan, MD (Dr. Panda) is a Child Neurologist and Assistant Professor with specialized interest and training in neuromuscular disorders in children. He is the Director of the Comprehensive Neuromuscular Program and Co-Director of the Muscular Dystrophy Association Care Center at ACH. He brings in training and expertise to perform electromyography and nerve conduction studies in children. Dr. Panda also has a particular interest in evaluating and treating children with headache disorders. He is the Medical Director of the Headache Clinic at ACH. 

Jahannaz Dastgir, DO

Jahannaz Dastgir, DO is a pediatric neuromuscular specialist and the clinical development lead of the RGX-202 program at Regenxbio. This program focuses on AAV8 gene therapy for Duchenne Muscular Dystrophy. 

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.